Cargando…
Benefits of Combined All-Trans Retinoic Acid and Arsenic Trioxide Treatment of Acute Promyelocytic Leukemia Cells and Further Enhancement by Inhibition of Atypically Expressed Transglutaminase 2
Randomized trials in acute promyelocytic leukemia patients have shown that treatment with a combination of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) is superior in efficacy to monotherapy, with significantly decreased mortality. So far, there are little data available to explain the...
Autores principales: | Jambrovics, Károly, Uray, Iván P., Keillor, Jeffrey W., Fésüs, László, Balajthy, Zoltán |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139906/ https://www.ncbi.nlm.nih.gov/pubmed/32168763 http://dx.doi.org/10.3390/cancers12030648 |
Ejemplares similares
-
Transglutaminase 2 programs differentiating acute promyelocytic leukemia cells in all-trans retinoic acid treatment to inflammatory stage through NF-κB activation
por: Jambrovics, Károly, et al.
Publicado: (2019) -
Transglutaminase 2 associated with PI3K and PTEN in a membrane-bound signalosome platform blunts cell death
por: Jambrovics, Károly, et al.
Publicado: (2023) -
All-trans-retinoic-acid and arsenic trioxide induced remission in promyelocytic blast crisis
por: Colvin, Teresa A., et al.
Publicado: (2018) -
Thrombocytosis in a patient with acute promyelocytic leukemia during treatment with all‐trans retinoic acid and arsenic trioxide
por: Habibi, Maryam, et al.
Publicado: (2021) -
Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives
por: McCulloch, Derek, et al.
Publicado: (2017)